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Objectives: The Hospital Universitario Germans Trias i Pujol is a 600-bed center serving 700,000 inhabitants 
including 1800 patients with HIV infection in Catalonia (Spain). Highly active antiretroviral therapy (HAART) 
became available at the end of 1996. Thus, the period 19951997 was considered appropriate for evaluating possible 
epidemiological changes in bloodstream infections (BSI) in HIV-infected patients. 
Methods: All significant bloodstream infections, including mycobacteremia and fungemia, observed in HIV-positive 
patients from January, 1995 to December, 1997 have been included in the study. 
Results: One hundred and eighty six cases were evaluated, in whom a decrease in BSI was observed (68 in 1995,86 
in 1996,32 in 1997). Over time, we observed an improvement in the immunologic situation of the patients (1995: 
CD4 <50/mm3 73.8% vs 1997: CD4 <50/mm3 45.5% (P=O.OS)). Th e source of BSI was known in 80.7% of the 
episodes. BSI secondary to catheter and respiratory infections prevailed in 1995, whereas an increase in bacteremias 
related to intravenous drug use, with or without endocarditis, was seen in 1997. The most frequent isolates were 
Mycobacterium avium intracellulare (23) (MAI), M. tuberculosis (20) Staphylococcus aureus (20), coagulase-negative 
staphylococci (16), Salmonella spp. (16) and Streptococcuspneumoniue (15). In 1997, a decrease was observed in the 
isolation of Gram-negatives and Mycobacterium spp. with S. aureus and enterococci prevailing. 
Conclusions: The prevalence of bloodstream infections in HIV-positive patients has decreased since the introduction 
of HAART and the immunologic state has improved. Furthermore there is a trend to a decrease or disappearance 
of microorganisms, such as Pseudomonas spp., Mycobacterium tuberculosis, MAI or fungi related to severe 
immunosuppression. Lastly, bacteremia caused by the active use of intravenous drugs remains stable with the highest 
percentage in Spain. 
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Bacterial infections are a frequent complication in 
patients with human immunodeficiency virus (HIV) 
infecti0n.i Severe qualitative and quantitative CD4 
defects and granulocytopenia favor these infections. 
Studies published at the beginning of the 1990s placed 
bacterial infections as the main cause of death in these 
patients.2 In 1995, Fichtenbaum et al. indicated that 
bacteremia continues to be a significant problem in 
HIV-infected individuals with a lower CD4 count. They 
reported an increase in staphylococcal infections and a 
decrease in respiratory infections emphasizing that the 
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mortality from these infections was similar to that of 
patients without HIV infection. These authors also 
stated that patients receiving AZT presented with a 
lower incidence of bacteremias, suggesting that an 
improvement in immune function positively influences 
the appearance of these infectious complications.3 In 
1996, new reverse transcriptase inhibitors (3TC and 
D4T) were introduced, followed shortly thereafter 
by the protease inhibitors. A substantial change in 
patient management, together with an increase in life 
expectancy, may have affected the epidemiology and 
clinical course of bloodstream infections (BSI) in these 
patients. 
The Hospital Universitario Germans Trias i Pujol is 
a 600 bed center serving 700,000 inhabitants including 
1800 patients with HIV infection as both outpatients 
and inpatients. It is also a reference center for HIV 
infection in Catalonia (Spain). 
The aim of the present study was to determine the 
clinical characteristics, etiology, and the clinical course of 
BSI, including mycobacteremia and fungemia occurring 
in HIV-positive patients from 1995 to 1997, and to 
evaluate the epidemiologic changes of this infectious 
complication over time. 
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PATIENTS AND METHODS 
Patients 
All significant BSI observed in patients with HIV 
infection from January, 1995 to December, 1997 have 
been included in the study. The cases were detected in 
the Clinical Microbiology Department of the Hospital, 
together with members of the Department of Infectious 
Diseases, who prospectively evaluated the clinical 
significance of all the BSI daily. BSI was defined as the 
presence of: (a) one positive blood culture for a patho- 
genic microorganism in the presence of systemic 
symptoms or a site of infection; or (b) two or more 
positive blood cultures for the same microorganism 
extracted at different times or from different sites. 
Other positive blood cultures were considered as 
contaminants. 
Methods 
Dejinition of the variables: A data collection protocol 
was retrospectively collected from patients’ files: 
Table 1. Etiologic agents of 186 episodes of bloodstream 
infection in HIV-positive patients 
Microorganism 
Gram-positive bacteria 
Staphylococcus aureus 
Coagulase-negative staphylococci 
Streptococcus pneumoniae 
fnterococcus spp. 
Streptococcus mitis 
Peptostreptococcus spp. 
Listeria monocytogenes 
Corynebacterium jeikeium 
Bacillus spp. 
Gram-negative bacteria 
Salmonella spp. 
Pseudomonas spp. 
fscherichia coli 
Enterobacter spp. 
Klebsiella pneumoniae 
Haemophilus influenzae 
Campylobacter jejuni 
Acinetobacter baumanii 
Serratia liquefaciens 
Atypical mycobacteria 
M. avium intracellulare 
M. kansasii 
M. xenopi 
Other mycobacterias 
Number of 
Episodes f%) 
67 36 
20 10.7 
16 8.6 
15 8 
8 4.3 
3 1.6 
1 0.5 
1 0.5 
1 0.5 
1 0.5 
51 27.4 
16 8.6 
14 7.5 
9 4.8 
4 2.1 
3 1.6 
2 1 
1 0.5 
1 0.5 
1 0.5 
32 17.2 
23 12.3 
3 1.6 
2 1 
4 2.1 
M. tuberculosis 20 10.7 
Fungi 12 6.4 
Cryptococcus neoformans 9 4.8 
Candida spp. 3 1.6 
Mixture of bacteria= 5 2.6 
a Gram-negative species only (1 case), gram-positive species (1 case), and 
mixed infections (3 cases). 
personal data, intrinsic and extrinsic risk factors, and 
data referring to the infectious episode and clinical 
course. HIV infection was classified according to the 
1993 AIDS definition criteria for adults and adolescents 
proposed by the Centers for Disease Control and 
Prevention-CDC.4 The diagnosis of hepatic cirrhosis 
required only clinical criteria. The diagnosis of diabetes 
mellitus was accepted when fasting glycemia was 
>140 mg/dl. A patient was considered a smoker when 
cigarette consumption > 10 cigarettes/day. Chronic 
obstructive pulmonary disease was based on clinical 
criteria and did not require functional criteria for 
diagnosis. Alcoholism was defined as the chronic intake 
of >80 g of alcohol/day. Diagnosis of heart failure was 
accepted when the patient required chronic diuretic or 
angiotensin inhibitors treatment or a previous episode 
of left cardiac failure. Chronic renal failure was defined 
by serum creatinine levels >2 mg/dl. With regard to 
extrinsic risk factors, a patient was considered to be an 
active injecting drug user (AIDU) when this habit had 
been maintained up to three months prior to the 
bacteremic episode. The administration of cytostatic 
drugs or corticoids was admitted when the patient had 
received one dose within the previous three weeks. The 
use of antibiotics was accepted when the patient had 
received any antibiotic within the previous 15 days. The 
performance of any type of endoscopic procedure was 
accepted within 48 hours prior to the infectious episode. 
BSI was considered to be of nosocomial origin when 
the febrile episode occurred after a minimum period of 
48 hours following hospital admission, or during the first 
seven days after hospital discharge. The remaining 
episodes were considered to be community acquired. 
The site of infection was determined with National 
Nosocomial Infection Surveillance (NNIS) criteria.5 In 
addition, one of three probability categories was 
assigned for each site of infection: a) definite: isolation 
of the same bacterial species from the blood and an 
NNIS-defined site of infection; b) probable: evidence of 
an NNIS-defined site of infection without microbiologic 
confirmation from the site of infection; c) possible: 
insufficient evidence to assign an NNIS-defined site of 
infection, but where the bloodstream isolate is com- 
monly associated with a particular site of infection (e.g., 
coagulase-negative staphylococci and an indwelling 
catheter). All BSI with definite, probable, or possible site 
Table 2. Sites of infection in patients with Gram-positive and 
Gram-negative bacteremia 
Sites of infection Gram-positive Gram-negative 
bacteremia bacteremia P 
(N=57) (%) (N=41) (“h) value 
Intravenous catheter 23 (40.3) 5 (12.1) 0.004* 
Respiratory tract 12 (21) 11 (26.8) 0.67 
Skin/soft tissue 10 (17.5) 1 (2.4) 0.017* 
Urinary tract 3 (5.2) 4 (9.7) 0.32 
Gastrointestinal 1 (1.7) 20 (48.7) <O.Ol* 
Endocarditis 8 (14) 0 (0) 0.019” 
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of infection were considered as secondary BSI. If the site 
of infection was unknown, the episode was considered 
as a primary BSI. Neither the origin of acquisition 
nor the source of infection were determined for 
Mycobacterium spp. bacteremia. 
Statistical method: Univariate analyses were performed 
using the Student’s t-test and the chi-squared test with 
or without Yate’s correction by a statistical package 
(SAS; SAS Inc., Cary, NC, USA). 
RESULTS 
Demographic data 
A total of 186 BSI occurred in 169 patients. BSI was 
observed in 150 males and in 19 females. The mean 
age was 33.1 +7.3 years. AIDS criteria were fulfilled in 
137 patients (91.3%), and 106 (64.2%) showed a CD4 
lymphocyte count lower than 50/mm3. Granulocyto- 
penia was present in 22 patients (15.6%). Regarding risk 
practices for HIV infection, 105 patients (69.5%) were 
or had been AIDU, 23 (15.2%) were men who had had 
sex with men (MSM), 16 (10.6%) were heterosexual, 
five (3.3%) had undergone blood transfusion, and one 
patient (0.7%) presented with several routes of 
transmission. 
Sixty-two patients (43.3 %) were receiving anti- 
retroviral treatment with nucleoside analogues and 15 
(9.3%) were being administered protease inhibitors. 
Intrinsic risk factors 
The intrinsic risk factors other than HIV infection were: 
smoking in 67 patients (35.8%), alcoholism in 33 
(17.6%) chronic obstructive pulmonary disease in 14 
(5%), hepatic cirrhosis in 32 (17.1%), diabetes mellitus 
in two (l%), heart failure in two (1%) chronic renal 
failure in two (l%), neoplasms in 19 (lO.l%), and 
splenectomy in three patients (1.6%). 
Extrinsic risk factors 
With regard to extrinsic risk factors for BSI, 30 (21.3%) 
patients were AIDU, seven (5%) had received steroids, 
and 12 (8.6%) had had chemotherapy. Eighty eight 
(65.2%) patients were undergoing prophylaxis with 
trimethoprim-sulfamethoxazole, and 22 (15.8%) were 
taking other antibiotics at the time of the BSI. 
Sixty five patients (47.5%) had intravenous catheters 
(63 peripheral venous catheters, two implantable 
[Portacath]), and 14 (10.4%) had undergone endoscopic 
investigation. 
Data on bacteremia 
One hundred and thirteen (83.7%) of the BSI were 
community acquired. A definite or probable source of 
infection was identified in 109 (80.7%) of the episodes. 
Indwelling intravenous catheter, respiratory, and 
gastrointestinal foci were the most frequent sites of 
infection in 29 (26.6%) 25 (22.9%) and 21 (19.3%) 
patients, respectively. Other sites of infection included 
the skin in 12 patients (ll%), the endocardium in nine 
(8.3%) the urinary tract in eight (7.3%) and other 
intraabdominal foci in five patients (4.6%). MA1 was 
the most frequently observed cause of BSI. Staphylo- 
coccus aureus, coagulase-negative staphylococci and 
Streptococcus pneumoniae were the most frequent 
Gram-positive etiologies. Salmonella spp. and Pseudo- 
monas spp. were the most prevalent gram-negative 
etiologies (Table 1). Intravenous catheters, skin/soft 
tissue, and endocarditis infections were significantly 
associated with Gram-positive bacteremia. In contrast, 
Table 3. Demographic characteristics of patients stratified by years 
Variables 
1995 
N=68 
(“?I 
7996 1997 
N=86 N=32 
f%) P/o) P-value 
Sex 
male 
female 
CD4 <50/MM3 
CD4 (50-200/mm3) 
CD4 (>200/mm3) 
AIDS 
Granulocyto-penia 
PFX TMP/SMX” 
Nucleosides 
Protease inhibitors 
AlDUb 
Intravenous catheter 
Corticosteroid therapy 
Chemotherapy 
Antibiotic therapy 
57 (90.4) 
6 (9.5) 
45/61 (73.8) 
7/61 (‘I 1.5) 
9/61 (14.8) 
50157 (87.7) 
8/54 (‘14.8) 
38/51 (74.5) 
22/52 (42.3) 
- 
11/56 (19.6) 
27/54 (50) 
3/55 (55) 
7/55 (12.7) 
12/55 (21.8) 
70 (88.6) 23 (85.1) 
9 (11.3) 4 (14.8) 
51/82 (62.2) IO/22 (45.5) 
21/82 (25.6) 7/22 (31.8) 
IO/82 (12.2) 5/22 (22.7) 
72/75 (96) 15/ 18 (83.3) 
IO/70 (14.3) 4/17 (23.5) 
39/68 (57.4) 1 l/l 6 (68.8) 
33/72 (45.8) 7/l 9 (36) 
1on3 (13.7) 5/l 9 (26.3) 
14/70 (20) 5/l 5 (33.3) 
31/68 (45.6) 7/l 6 (43.8) 
4/69 (5.8) 0115 (0) 
5/ 69 (7.2) 0115 (0) 
9/68 (13.2) l/l 5 (6.7) 
0.76 
0.05* 
0.05* 
0.46 
0.10 
0.62 
0.14 
0.39 
-co.01 * 
0.48 
0.85 
0.63 
0.25 
0.25 
a Prophylaxis with trimethoprim/sulphamethoxazole. 
b Active injecting drug use. 
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gastrointestinal infections were significantly associated 
with Gram-negative bacteremia (Table 2). With regard 
to CD4 counts ( <50/mm3), patients with gram-positive 
bacteremia had a significantly higher count (2.5/55; 
45.5%) than the other groups (81/110;73%) (P=O.O007). 
Furthermore, patients with Gram-positive bacteremia 
were more frequently AIDU (18/55; 32.7%) than 
the other groups of BSI (12/86; 13.9%) (P=O.O14). 
Attributable in-patient mortality was assessed for all 
deaths. In 39 (22.5%) patients, BSI was judged to have 
either contributed to or caused the terminal event. On 
examining the mortality by groups of microorganisms, 
the highest rate was related to BSI by M. tuberculosis 
(37.5%) and the lowest rate was attributed to gram- 
positive bacteremias (15.4%). The mortality observed 
by gram-negative bacteria was 12 out of 49 patients 
(24.5%), 3/12 patients (25%) by fungi, 7/26 patients 
(26.9%) by atypical mycobacteria and l/5 patients (20%) 
by mixed bacteremia. 
Occurrence of BSI over time 
Demographic characteristics: We observed a clear 
decrease in the number of BSI in 1997, especially 
considering that we were attending a similar HIV 
population each year (1800 per year). The demographic 
characteristics and the extrinsic risk factors of the 
patients stratified by years are shown in Table 3 and did 
not vary significantly over time except in the CD4 
counts and in the use of protease inhibitors. 
Data on bacteremia: As shown in Table 4, nonsignificant 
increases were observed in bacteremia from cutaneous 
and endocardic sites, which represented the two most 
frequent sources of BSI in 1997. It is also of interest to 
mention a nonsignificant increase in the urinary tract 
site in 1997. In contrast, the respiratory and catheter 
sites were the most frequent source of BSI in 1995 and 
showed a marked but nonsignificant decrease in 1997. 
The gastrointestinal site remained in an intermediate 
position. When we looked at the BSI by groups of 
microorganisms (Table 5), a significant increase in 
enterococcal bacteremia and a significant decrease in 
gram-negative bacteremia, mainly in Pseudomonas spp., 
and in hematogenous tuberculosis, were observed over 
time. The nonsignificant decrease of disseminated 
atypical mycobacteria, mainly in MAI, and fungi seen in 
1997 is also of interest. 
When we looked at mortality, there was a 
nonsignificant decrease (23.1% in 1995,24.4% in 1996, 
and 16% in 1997) from 1995 to 1997. 
DISCUSSION 
This study included all the HIV-positive patients (both 
in- and outpatients) of our hospital, who presented with 
Table 4. Source of secondary bloodstream infections stratified by years 
Variables 
1995 1996 1997 
N=37 N=52 N=20 
(“h) (“/o) 06) P-value 
Respiratory 8 (21.6) 14 (26.9) 3 (15) 0.54 
Catheter 13 (35.1) 13 (25) 3 (15) 0.24 
Gastrointestinal 7 (18.9) 11 (21.1) 3 (15) 0.83 
Cutaneous 3 (8.1) 5 (9.6) 4 (20) 0.35 
Endocarditis 2 (5.4) 3 (5.7) 4 (20) 0.10 
Intra-abdominal foci 2 (5.4) 3 (5.7) - 0.55 
Urinary 2 (5.4) 3 (5.7) 3 (15) 0.34 
Table 5. Etiologic agents of bloodstream infection stratified by years 
Micro-organisms 
Gram-positive 
5. aureus 
CN-staphylococci 
5. pneumoniae 
Enterococcus spp. 
Gram-negative 
Salmonella spp. 
Pseudomonas spp. 
Escherichia 
M. tuberculosis 
Atypical mycobacteria 
M. avium intracel/ulare 
Fungi 
1995 1996 1997 
N=68 N=86 N=32 
f%) (“/o) (%) 
24 (35.3) 27 (31.4) 15 (46.9) 
5 (7.4) 11 (12.8) 4 (12.5) 
8 (11.8) 5 (5.8) 3 (9.4) 
7 (10.3) 5 (5.8) 3 (9.4) 
1 (1.5) 3 (3.5) 4 (12.5) 
12 (17.6) 31(36) 8 (25) 
3 (4.4) ll(12.8) 2 (6.3) 
2 (2.9) ll(12.8) 1 (3.1) 
3 (4.4) 3(3.5) 3 (9.4) 
13 (19.1) 4(4.7) 3 (9.4) 
15 (22.1) 14(16.3) 3 (9.4) 
9 (13.2) 12(14) 2 (6.3) 
4 (5.9) 8(9.3) 0 (0) 
P-value 
0.29 
0.52 
0.41 
0.57 
0.035x 
0.037" 
0.16 
0.04* 
0.40 
0.01* 
0.27 
0.50 
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an episode of BSI, between 1995 and 1997. HAART 
became available in our hospital at the end of 1996. A 
reduction has recently been reported in the morbidity 
and mortality of HIV-positive patients directly related 
to the use of the new antiretroviral treatment combina- 
tions.‘j Likewise, it has recently been reported that 
HAART decreases the incidence of bacteremia in 
individuals with HIV infection.7 We therefore con- 
sidered the time period from 1995 to 1997 to be appro- 
priate for evaluating any changes in the characteristics 
of BSI in these patients. 
A total of 187 cases of BSI were evaluated in the 
study. Interestingly, we observed a decrease in the 
number of episodes over the study period (68 in 1995, 
86 in 1996 to 32 in 1997), despite the relatively constant 
number of HIV-positive patients followed by the 
institution over this time. Most of the patients with BSI 
were male (88.7%) with HIV infection stage C3 (91.3%), 
similar to what has been published in other series.* 
These data did not show any important changes during 
the study period. In almost two thirds of the patients, the 
CD4 count was lower than 50/mm3. However, a signifi- 
cant improvement in this variable was observed during 
the last year of the study with less than half of the 
patients having fewer than 50/mm3 CD4. Although 
many patients in this series were taking nucleoside 
analogs, the greatest difference by year was found in the 
administration of protease inhibitors, representing 
26.3% of the patients with BSI in 1997 versus 0% in 
1995. 
The possible coexistence of chronic, debilitating 
diseases other than HIV infection was evaluated and 
was found to be of little relevance, except for hepatic 
cirrhosis and neoplasms involving 17.1% and 10.1% of 
the patients, respectively. In regard to the extrinsic risk 
factors for the appearance of BSI, the increase in the use 
of intravenous drugs (up to one third of the patients 
in 1997) and the decrease in the administration of 
corticoids, cytostatic drugs, antibiotics, and in the use of 
intravenous catheters is of note over time. 
The origin of infections was mainly community 
acquired and did not show any changes throughout the 
study period. Interestingly, the source of infection 
was determined in a high percentage of cases (80%), 
contrary to other series in which this percentage did 
not surpass 50%.9 Important changes were observed in 
regard to the origin of BSI. In 1995, BSI secondary to 
catheter infection and respiratory infections prevailed. 
Of the patients with catheters, 35.1% developed BSI, a 
rate similar to that in other studies carried out at the 
beginning of the 1990~.~ The association of BSI with 
intravenous catheters in HIV-positive patients is well 
known and several studies have shown that catheter- 
related infections are more prevalent in HIV-positive 
patients.iO-l2 This circumstance may be justified by the 
compromised immune status and the need for repeated 
administration of intravenous therapy in this group.This 
is in agreement with the fact that HIV-positive patients 
were severely immunosuppressed prior to receiving 
HAART and thus they frequently required intravenous 
therapy for treating opportunistic infections or neo- 
plasms such as Kaposi’s sarcoma. In 1996, a non- 
significant fall was observed in infection caused by 
catheters, and there was a considerable rise in respira- 
tory infections with a marked increase in pneumonias by 
Pseudomonas spp. Several studies have reported this 
problem, indicating that classical predisposing factors 
for Pseudomonas infection, such as granulocytopenia 
and the use of corticoids, are not usually present in HIV- 
positive patients. To the contrary, the main risk factors 
of this infectious complication are previous diagnosis of 
AIDS, a greater number of opportunistic infections or 
hospitalizations, and the use of antibiotics in the two 
weeks prior to the episode of bacteremia.13,14 Although 
these data were not analyzed in this study, we believe 
that Pseudomonas spp. bacteremia is a severe infection 
generally involving HIV-positive patients in an advanced 
stage of the disease, such as the patients included in 1996 
prior to the use of highly active antiretroviral therapy. 
Finally, from the 1997 data, we observed a marked but 
non-significant decrease in BSI of respiratory origin, 
from the disappearance of pneumonia by Gram-negative 
bacteria (Pseudomonas and others), as well as a 
nonsignificant decrease in BSI secondary to the use of 
catheters, undoubtedly related to the decrease in the use 
of these devices. In contrast, we observed an increase in 
BSI related to the use of intravenous drugs, with or 
without endocarditis, coinciding with a notable relative 
increase observed in the active use of these drugs in the 
patients with BSI in 1997. Likewise, a non-significant rise 
was found in the BSI of urinary tract origin in 1997, 
compared with those of 1995 and 1996, although the 
reason for this remains to be clarified. Gastrointestinal 
infections remained stable throughout the study and 
were the cause of BSI in 15 to 20% of the cases. 
The changes observed on analyzing the sources of 
bacteremia in HIV-positive patients may be related to 
the changes seen in the causative microorganisms. Thus, 
analysis of the global series indicated: (a) the prevalence 
of Gram-positive bacteria as a group, and (b) the 
predominance of MAI, M. tuberculosis, S. aureus, 
coagulase negative staphylococci, Salmonella spp and S. 
pneumoniae, as individual microorganisms. When the 
BSI were stratified by year, interesting data were found. 
In 1997 there was a greater percentage of Gram-positive 
bacteremias than in other years, although not by 
S. aureus as expected, but rather by E. faecalis without a 
clear relationship to AIDU. A significant decrease in 
Gram-negative bacteremia, mainly in Pseudomonas spp. 
was observed. As reported in other series, the BSI by 
atypical mycobacteria, especially by MAI, markedly 
decreased.i5 Hematogenous tuberculosis significantly 
decreased and was very infrequent in 1997, and the 
fungemias disappeared. 
In conclusion, a marked decrease in the prevalence 
of BSI occurred after the introduction of protease 
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inhibitors, presumably related to the improvement in 
the immunologic status of the outpatient population. 
Furthermore, there is a trend to a decrease or disappear- 
ance of microorganisms, such as Pseudomonas spp., 
Mycobacterium tuberculosis, MA1 or fungi, related to 
severe immunosuppression. Lastly, the BSI related 
to the active use of intravenous drugs remains stable and 
make up the greater percentage in Spain. 
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